Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Oncimmune (ONC)

Price 11.00p on 19-07-2024 at 16:30:00
Change 0.00p 0%
Buy 11.90p
Sell 10.10p
Buy / Sell ONC Shares
Last Trade: -
Day's Volume: 0
Last Close: 11.00p
Open: 11.00p
ISIN: GB00BYQ94H38
Day's Range 0.00p - 0.00p
52wk Range: 9.35p - 30.20p
Market Capitalisation: £8m
VWAP: 0.00p
Shares in Issue: 74m

Recent Trades History Oncimmune (ONC)

Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for Oncimmune

Time period:
to
Date Open High Low Close Volume

Share News for Oncimmune

EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss

21st May 2024 16:27

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout

29th Feb 2024 17:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

19th Feb 2024 12:54

Read More

TRADING UPDATES: SkinBio launches food supplement on Amazon

30th Nov 2023 14:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Oncimmune shares jump following new strategy update

12th Oct 2023 14:21

Oncimmune Holdings PLC - Nottingham, England-based immunodiagnostics developer - Announces plans to focus on higher value customers, penetrating key accounts, partnering with key technology suppliers and launching new tools. Intends to accelerate new commercial contracts through partnerships with more contract research organisations to expand customer base, leverage auto-antibody analysis capabilities across new areas like companion diagnostics, and augment its commercial team. Also plans to expand its business models "beyond price-per-sample to more strategic partnership models" with upfront project and milestone success fees to better reflect its value. Update follows the disposal of Oncimmune Ltd in May, and the hiring of Martin Gouldstone as chief executive officer and Martin Hudson as finance director in August and September respectively. Company says final results for year ended August 31 will be released in due course. Read More

FTSE 100 Latest
Value8,155.72
Change-49.17

Login to your account

Forgot Password?

Not Registered